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Abstract
Proteases have been implicated in a variety of developmental processes during the malaria
parasite lifecycle. In particular, invasion and egress of the parasite from the infected hepato-
cyte and erythrocyte, critically depend on protease activity. Although falcipain-1 was the first
cysteine protease to be characterized in P. falciparum, its role in the lifecycle of the parasite
has been the subject of some controversy. While an inhibitor of falcipain-1 blocked erythro-
cyte invasion by merozoites, two independent studies showed that falcipain-1 disruption did
not affect growth of blood stage parasites. To shed light on the role of this protease over the
entire Plasmodium lifecycle, we disrupted berghepain-1, its ortholog in the rodent parasite
P. berghei. We found that this mutant parasite displays a pronounced delay in blood stage
infection after inoculation of sporozoites. Experiments designed to pinpoint the defect of ber-
ghepain-1 knockout parasites found that it was not due to alterations in gliding motility, hepa-
tocyte invasion or liver stage development and that injection of berghepain-1 knockout
merosomes replicated the phenotype of delayed blood stage growth after sporozoite inocu-
lation. We identified an additional role for berghepain-1 in preparing blood stage merozoites
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for infection of erythrocytes and observed that berghepain-1 knockout parasites exhibit a
reticulocyte restriction, suggesting that berghepain-1 activity broadens the erythrocyte rep-
ertoire of the parasite. The lack of berghepain-1 expression resulted in a greater reduction in
erythrocyte infectivity in hepatocyte-derived merozoites than it did in erythrocyte-derived
merozoites. These observations indicate a role for berghepain-1 in processing ligands
important for merozoite infectivity and provide evidence supporting the notion that hepatic
and erythrocytic merozoites, though structurally similar, are not identical.
Author summary
Malaria affects hundreds of millions of people and is the cause of hundreds of thousands
of deaths each year. Infection begins with the inoculation of sporozoites into the skin dur-
ing the bite of an infected mosquito. Sporozoites subsequently travel to the liver, where
they invade and replicate in hepatocytes, eventually releasing the stage of the parasite that
is infectious for red blood cells, termed merozoites. Hepatic merozoites initiate blood
stage infection, the stage that is responsible for the clinical symptoms of malaria. The
blood stage of the parasite grows through repeated rounds of invasion, development and
egress of blood stage merozoites, which then continue the cycle. Proteases are among the
enzymes that are essential for parasite survival and their functions range from invasion of
red blood cells, to the breakdown of red cell hemoglobin, to the release of parasites from
red cells. As the function of the cysteine protease falcipain-1 in the lifecycle of the human
malaria parasite Plasmodium falciparum remains poorly understood, we decided to study
berghepain-1, the orthologue of the rodent malaria parasite P. berghei by generating a ber-
ghepain-1 deletion parasite. Using this mutant, we demonstrate that berghepain-1 has a
critical role in both hepatic and erythrocytic merozoite infectivity. Little is known about
differences between these two types of merozoites and our data leads us to conclude that
these merozoites are not identical.
Introduction
Malaria, caused by parasites of the genus Plasmodium, continues to be a global health prob-
lem, causing significant morbidity and mortality particularly in resource poor settings [1].
Human infection begins with the injection of sporozoites into the skin where, using gliding
motility, they find and enter the blood stream, carrying the parasites to the liver [2]. Here,
they invade hepatocytes and develop into exo-erythrocytic forms (EEFs), replicating to pro-
duce thousands of hepatic stage merozoites. Once mature, these liver stage merozoites bud
from the infected hepatocytes and enter the blood stream in packets termed merosomes [3].
Hepatic merozoites are released from merosomes and invade erythrocytes, where they
develop and divide to produce daughter blood stage merozoites. Infected red blood cells
eventually rupture to release the newly formed merozoites that can then go on to invade
new red blood cells. Thus, an iterative cycle of parasite replication is established, leading to
high numbers of parasite-infected erythrocytes in the host blood stream and clinical symp-
toms of malaria. A proportion of erythrocytic stage parasites differentiate to sexual stage
parasites, which are transmitted to the mosquito as it takes a blood meal. Fertilization
occurs in the mosquito midgut and the parasite migrates across the midgut wall to form
oocysts containing sporozoites that are released and invade the salivary glands to be injected
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during the next blood meal. With the emergence of insecticide-resistant mosquitoes and
parasites that are increasingly resistant to available antimalarial drugs, there is an urgent
need for the identification of new drug targets.
Cysteine proteases play key roles at multiple stages of the Plasmodium life cycle, including
functions in host cell invasion [4–6], hemoglobin degradation [7,8] and facilitation of parasite
egress from hepatocytes [3] and erythrocytes through cleavage of both parasite proteins [9,10]
and erythrocyte ankyrin [11]. Of the 33 putative cysteine proteases encoded in the P. falciparum
genome [12], the falcipain family of papain-like cysteine proteases contains four members, with
falcipain-2 and -3 having well-established roles in the degradation of host erythrocyte hemoglo-
bin in the parasite food vacuole [13–17]. While falcipain-1 was the first cysteine protease to be
characterized in P. falciparum [18], its physiological role in the lifecycle of the parasite still
remains poorly understood. Compared to falcipain-2 and -3, which are similar in sequence
(68% of sequence identity), falcipain-1 shares only 38–40% of sequence identity to the other fal-
cipains. Falcipain-1 was detected in the transcriptome [19] and proteomes of asexual and sexual
erythrocytic stages of the parasite, as well as in the sporozoite stage [20–22]. Based on the gener-
ation of an inhibitor for falcipain-1, it was suggested that this protease plays an important role
in merozoite invasion of erythrocytes [23]. These data are consistent with many lines of evi-
dence showing that proteases are required for host cell invasion by Apicomplexan parasites, spe-
cifically for processing of surface proteins to expose adhesive domains and to release adhesive
interactions ([24–28], reviewed in [9]) and with a previous study that found deletion of the
rodent ortholog of falcipain-1 resulted in a blood stage growth defect [13]. Interpretation of
these results has been complicated by two subsequent studies which found that deletion of falci-
pain-1 in P. falciparum lines 3D7 and D10 did not impact growth of erythrocytic stages of the
parasite [17,29,30].
Given the controversy surrounding the role of falcipain-1 in merozoite invasion, and the
possibility that it might function in mosquito stages, we proposed to shed light on the role of
falcipain-1 by studying its ortholog in the rodent parasite P. berghei. Rodent malaria parasites
have a smaller repertoire of falcipain-family proteases compared to P. falciparum with only
one ortholog with similarity to falcipain-2/-3 identified. However, orthologs of falcipain-1
exist in all Plasmodium species studied to date [13,15]
In the present study, we generated a deletion mutant of berghepain-1, (PBANKA_132170)
as well as an epitope-tagged berghepain-1 parasite. Our results support a role for berghepain-1
in hepatic and erythrocytic merozoite infection of erythrocytes and in particular point to a
function of this protease in infection of mature red blood cells. Importantly, we find that
hepatic merozoite infectivity is impaired more than infectivity of blood stage merozoites,
indicative of differences between these two types of merozoites.
Results
Berghepain-1 is not required in the mosquito vector
To investigate whether berghepain-1 is critical P. berghei development we generated berghe-
pain-1 deletion or ‘knockout’ (BP1-KO) parasites by replacing the berghepain-1 open reading
frame with a drug selection cassette, using the flanking untranslated regions to target the locus
for homologous recombination (S1 Fig). Two independent transfections were performed and
verification of berghepain-1 deletion was performed by PCR and protein deletion was verified
using a probe that binds to the berghepain-1 protein (S2 Fig). One clone from each transfec-
tion, designated BP1-KO clone 1 and BP1-KO clone 2, were characterized. Data shown dis-
plays combined results obtained using both clones, when indicated. To control for effects
due to manipulation of the genetic locus, a berghepain-1 control parasite (BP1-CON) was
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generated using a targeting plasmid containing the entire berghepain-1 gene with its endoge-
nous 5’ and 3’ regulatory elements, as well as the selectable marker cassette (S1 Fig). Each con-
struct was transfected into GFP-expressing P. berghei ANKA clone 507cl1 [31], a strain lethal
to mice.
A. stephensi mosquitoes were infected with both berghepain-1 knockout clones, as well as
the control line BP1-CON and development from oocyst to salivary gland sporozoites was fol-
lowed. Both BP1-KO clone 1 and BP1-KO clone 2 parasites were compared to the control line
BP1-CON and were found to generate normal numbers of oocysts (Fig 1A), and salivary gland
sporozoites (Fig 1B), indicating that berghepain-1 does not have a crucial role at these stages of
the parasite life cycle.
Gliding motility is key for sporozoite migration out of the inoculation site and for infection
of hepatocytes upon arrival in the liver [[32,33], reviewed in [2]]. To test whether berghepain-1
knockout sporozoites are motile and viable, we performed an in vitro gliding motility assay,
quantifying the proportion of motile salivary gland sporozoites and the trails they leave behind.
As sporozoites glide, they deposit trails of surface proteins, such as the circumsporozoite pro-
tein (CSP), which can be stained and trails can be manually counted [34]. Motility of BP1-KO
sporozoites was comparable to that of control parasites, indicating that berghepain-1 does not
have a critical role in sporozoite gliding motility (Fig 1C).
Delayed prepatent period of berghepain-1 knockout sporozoites
To investigate the infectivity of berghepain-1 knockout sporozoites, we inoculated mutant and
control sporozoites intravenously (i.v.) into mice and determined the time to detectable blood
stage infection, termed the prepatent period, by Giemsa-stained blood smears. Typically in
Fig 1. Berghepain-1 knockout parasites develop normally in the mosquito and sporozoites are motile. A. Oocyst formation. Midguts were
dissected 13 days after the infectious blood meal and GFP-positive oocysts were counted. Horizontal lines represent mean values. Shown are
pooled results from two independent experiments using BP1-CON and BP1-KO clone 1, and one experiment using BP1-CON and BP1-KO clone 2.
B. Salivary gland sporozoite numbers. Salivary glands were isolated from 20 mosquitoes, 19 days after the infectious blood meal, and
sporozoites were counted. Shown are the mean and standard deviation of sporozoite numbers per mosquito, obtained from four independent
experiments using BP1-CON and BP1-KO clone 1, and one experiment using BP1-CON and BP1-KO clone 2. C. Gliding motility. BP1-CON and
BP1-KO sporozoites were allowed to glide for 1 h at 37˚C on coated glass coverslips and trails were visualized by detection of shed surface protein
CSP. A total number of 2181 BP1-CON and 3189 BP1-KO sporozoites with and without trails were counted and the percent of sporozoites
associated with the indicated number of circular trails is shown. Both clones of BP1-KO parasites were analyzed and results were pooled.
https://doi.org/10.1371/journal.ppat.1006586.g001
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mice, an i.v. inoculum of 100 or 1,000 wild-type sporozoites results in detectable blood stage
parasites with a prepatent period of three and four days, respectively, with each day of delay
indicating an approximate 10-fold reduction in the infectious inoculum or in the downstream
events ultimately leading to detectable blood-stage parasites [35]. Following inoculation of 100
to 10,000 sporozoites into C57BL/6 and Swiss Webster mice, many of the mice inoculated with
BP1-KO clone 1 or clone 2 sporozoites failed to develop blood stage parasitemia (Table 1). Of
those mice that developed parasitemia, the prepatent period of BP1-KO sporozoites was con-
sistently delayed by approximately four days compared to mice inoculated with the same num-
ber of BP1-CON sporozoites (Table 1).
Berghepain-1 knockout sporozoites invade and develop normally in the
liver
Given the delay in prepatent period after injection of BP1-KO sporozoites compared to con-
trols, we set out to systematically investigate sporozoite infection and development in the liver,
to identify the stage at which berghepain-1 is required. To assess the liver infectivity of
BP1-CON and BP1-KO parasites in vivo, 10,000 BP1-KO or BP1-CON salivary gland sporozo-
ites were injected i.v. or intradermally (i.d.) and 40 h post infection livers were harvested for
quantification of Pb18S rRNA. No significant reduction of BP1-KO liver stage growth com-
pared to BP1-CON was found by either route of inoculation (Fig 2A and S3 Fig, respectively),
suggesting that berghepain-1 is not required for sporozoite exit from the dermis or infection
and development in the liver.
To further investigate EEF development, BP1-CON and BP1-KO sporozoites were allowed
to invade HepG2 cells in vitro. At 60 h post infection, cells were fixed and EEFs were manually
counted and their diameter was measured. BP1-KO parasites showed robust development in
vitro and no differences in the number or size of EEFs were observed (Fig 2B and 2C). Follow-
ing this, we imaged the different stages of EEF development in vitro. After an initial growth
phase, nuclear division occurs and the parasite membrane invaginates to form the cytomere
stage [36]. Subsequently, individual hepatic merozoites bud from each cytomere to form a
mature EEF full of hepatic merozoites. MSP1, the major surface protein of merozoites [37] is
observed lining the cytomeres and then localizes to individual hepatic merozoites [38]. At 56 h
and 72 h post infection, BP1-CON and BP1-KO EEFs were stained for MSP1, which showed
that the cytomere and late schizont stages in BP1-KO parasites are morphologically indistin-
guishable to control EEFs (Fig 2D). The numbers of cytomere stage and fully mature EEFs
Table 1. In vivo infectivity of berghepain-1 knockout sporozoites as determined by prepatent period. C57BL/6 or Swiss Webster mice were inocu-
lated i.v. with the indicated number of sporozoites. Blood smears were examined daily starting on day 3 after sporozoite inoculation and mice were considered
negative if parasites were not detected by day 20. For C57BL/6 mice, data from three independent experiments are pooled; two with BP1-KO clone 1 and one
with BP1-KO clone 2. For Swiss Webster mice, data from two independent experiments using BP1-KO clone 1 are pooled.
Mouse line Parasite Dose #mice infected
#mice inoculated
Prepatent period (days)
C57BL/6 BP1-CON 100 10/10 (100%) 3.8
BP1-CON 1,000 10/10 (100%) 3.0
BP1-KO 100 6/15 (40%) 7.5
BP1-KO 1,000 13/15 (86%) 7.0
Swiss Webster BP1-CON 1,000 10/10 (100%) 4.2
BP1-CON 10,000 10/10 (100%) 3.1
BP1-KO 1,000 3/15 (20%) 7.5
BP1-KO 10,000 7/10 (70%) 8.5
https://doi.org/10.1371/journal.ppat.1006586.t001
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were also counted in these experiments and there were no differences between controls and
BP1-KO parasites. Overall, these data suggest that berghepain-1 is not required for liver stage
growth or maturation of P. berghei.
Normal merosome formation and parasitophorous vacuole rupture in
berghepain-1 knockout liver stage parasites
In order to successfully release infective merozoites into the blood, the parasitophorous vacu-
ole membrane (PVM) enclosing the EEF ruptures to release hepatic merozoites into the cyto-
plasm of the hepatocyte. These then bud from the hepatocyte in packets termed merosomes
to enter the blood stream [3,39]. Given the involvement of cysteine proteases in both PVM
rupture and the release of merosomes [3], we speculated that berghepain-1 might be involved
in this process. We quantified the number of merosomes and detached cells, which contain
ruptured EEFs, released into culture supernatants at 65 h post infection and normalized this
number to the number of EEFs present at 48 h post infection. For clarity, we will refer to mero-
somes and detached cells as merosomes throughout the manuscript. After 65 h of in vitro cul-
ture, we found that compared to BP1-CON parasites, similar numbers of merosomes were
produced by BP1-KO clone 2 (Fig 3A) and BP1-KO clone 1 (S4 Fig).
To evaluate merosome morphology and loss of the PVM in berghepain-1 knockout mero-
somes we fixed and stained merosomes with antibodies to MSP1, to visualize individual mero-
zoites, and UIS4 [up-regulated in infective sporozoites gene 4 [40]], a marker for the PVM
[41]. A previous study demonstrated that PV rupture occurs in the infected hepatocyte and is
immediately followed by merosome formation [39] so we would not expect to see UIS4 stain-
ing on properly developed merosomes. Staining for MSP-1 showed normal segregation of
merozoite membranes (Fig 3B) and staining for UIS4, showed normal loss of the parasitophor-
ous membrane (Fig 3C), suggesting that berghepain-1 knockout merosomes have normal mor-
phology. Together, these data demonstrate that BP1-KO parasites develop into EEFs and form
morphologically normal merozoites and merosomes.
Berghepain-1 is critical for hepatic merozoite infectivity
To test whether the BP1-KO merosomes produce infectious hepatic merozoites, we collected
merosomes from in vitro cultures of BP1-CON and BP1-KO parasites, 60–65 h post-infection
of HepG2 cells. Upon i.v. injection of five BP1-CON merosomes, mice became positive for
blood stage parasites on day 4 after inoculation. In contrast, mice injected with BP1-KO exhib-
ited a significant delay in prepatent period, with mice developing detectable parasitemia on
day 9 after injection (Fig 4A).
Given that egress of Plasmodium blood-, liver- and mosquito-stages relies on protease activ-
ity [42] one possible explanation for this delay is that berghepain-1 may participate in the
Fig 2. Normal in vivo and in vitro growth of berghepain-1 knockout liver stage parasites. A. Development of
berghepain-1 knockout liver stage parasites in vivo. 10,000 BP1-CON or BP1-KO sporozoites were injected i.v. into
Swiss Webster or C57BL/6 mice. RT-qPCR analysis of liver RNA 40 h after infection found no significant reduction of
BP1-KO liver stage growth as measured by parasite 18S rRNA copy number. Results from one representative experi-
ment using BP1-CON and BP1-KO clone 1, from a total of three experiments, is shown. B. & C. Development and size
of berghepain-1 knockout EEFs in vitro. HepG2 cells were infected with BP1-CON and BP1-KO parasites and at 60 h
post infection the number of EEFs was counted (B) and their sizes measured (C). Pooled results of two independent
experiments, one using BP1-KO clone 1 and one using BP1-KO clone 2 are shown. D. Immunofluorescene assays of
late liver stage berghepain-1 knockout parasites. HepG2 cells infected with either BP1-CON or BP1-KO clone 1
sporozoites were fixed 56 h (cytomere stage) and 72 h (mature EEF) post-infection. EEFs were stained for MSP1 to
visualize the parasite membrane (magenta) and DNA was stained with DAPI (blue). Scale bars: 10 μm.
https://doi.org/10.1371/journal.ppat.1006586.g002
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rupture of the merosome membrane and subsequent egress of the hepatic merozoites. Since
infection by Plasmodium is known to alter the stiffness of hepatocyes, reducing their deform-
ability [43], we hypothesized that the delay in prepatent period of BP1-KO parasites after injec-
tion of merosomes could be due to an altered elasticity of the merosome membrane, which
would change its ability to rupture. To investigate this, we tested the elasticity of the membrane
surrounding BP1-CON and BP1-KO merosomes by atomic force microscopy (AFM). No sig-
nificant difference in merosome rigidity, represented by the Young’s modulus, a mechanical
property of elastic solid materials [43], was found between populations of BP1-KO clone 1 and
clone 2 and BP1-CON merosomes (Fig 4B), suggesting normal elasticity of the merosome
membrane of BP1-KO parasites.
To further investigate whether reduced infectivity of BP1-KO merosomes was due to
impaired merozoite release from the merosomes, we injected 5000 unruptured or mechani-
cally ruptured merosomes into mice. Merosomes were mechanically disrupted with 10 strokes
through a 30 gauge needle and immediately injected i.v. into mice. Microscopy of both BP1-
CON and BP1-KO merosomes subject to this procedure confirmed that merozoites from 98%
of merosomes were released. Upon injection of 5000 ruptured merosomes of the control para-
site BP1-CON, parasites were detectable by Giemsa-stained blood smear after an average of
1.9 days (Fig 4C). In contrast, injection of the same number of ruptured merosomes of the
BP1-KO parasite resulted in detectable blood stage parasitemia at an average of 7.7 days after
injection, similar to the prepatent period of unruptured BP1-KO merosomes (Fig 4C). Thus,
BP1-KO hepatic merozoites, when mechanically released from merosomes, have the same
impairment in their ability to establish a blood stage infection as their unruptured counter-
parts. These data demonstrate that berghepain-1 knockout hepatic merozoites are not ade-
quately primed for erythrocyte invasion, and suggest a critical role for berghepain-1 in
preparing hepatic merozoites for the successful infection of red blood cells either during the
development of hepatic merozoites within the EEF or at the time of merozoite invasion of the
red blood cell, or both.
Attenuated growth and lethality of berghepain-1 knockout blood stage
parasites
Given the previous finding that falcipain-1 functions during blood stage merozoite invasion of
erythrocytes [23], and our current finding that berghepain-1, the ortholog of falcipain-1, likely
functions during hepatic merozoite infection of erythrocytes, we set out to characterize the ber-
ghepain-1 knockout parasite in the blood stage. After infection with P. berghei ANKA blood
stage parasites, parasitemia of susceptible mice typically rises rapidly and mice die within 7–8
days of experimental cerebral malaria, a syndrome characterized by inflammation in the brain
and other organs [44–46]. We compared the growth of BP1-CON and BP1-KO parasites by
inoculating equal numbers of infected red blood cells i.v. into Swiss Webster mice and monitor-
ing parasitemia and survival of infected mice (Fig 5). All BP1-CON infected mice showed a
rapid increase in parasitemia and death by day 8 post-infection. In contrast, in BP1-KO-infected
Fig 3. Normal merosome formation in berghepain-1 knockout liver stage parasites. HepG2 cell monolayers
were infected with BP1-CON and BP1-KO parasites, and merosomes were quantified and evaluated by
immunofluorescence assays. A. Quantification of merosomes. The number of merosomes from BP1-CON and
BP1-KO parasites released into the culture supernatant at 65 h post infection were counted and expressed as
percentage of EEFs present at 48 h post infection. Results of four experiments performed using BP1-CON and
BP1-KO clone 2 are pooled and shown. B-C. Immunofluorescene assays. Merosomes of BP1-CON and
BP1-KO clone 1 parasites were collected at 65 h post infection and stained for MSP1, to visualize individual
merozoites, or UIS4 (up-regulated in infective sporozoites), to visualize the parasitophorous membrane
(magenta). Parasites express GFP (green) and DNA was stained with DAPI (blue). Scale bars: 15 μm.
https://doi.org/10.1371/journal.ppat.1006586.g003
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Fig 4. Berghepain-1 knockout merosomes have reduced infectivity. A. Detection of blood stage
parasitemia following injection of merosomes. Five merosomes of BP1-KO or BP1-CON parasites were
injected i.v. per mouse and parasitemia was monitored daily for 11 days. Results from two representative
experiments are shown and the average daily parasitemia ±SD of 5 mice infected with BP1-CON and 6 mice
infected with BP1-KO clone 2 are plotted. B. Atomic force microscopy of the merosome membrane.
Merosomes of BP1-CON and BP1-KO parasites were fixed and subject to AFM to measure Young’s modulus (E).
Cell elasticity was measured on one point of each cell adhered to a poly-L-lysine-coated glass slide with 5 force-
distance curves per cell. Data is displayed in a Tukey box and whisker plot, with a horizontal line representing the
median and individually plotted outlier values. Shown are pooled values of seven independent experiments, four
performed with BP1-KO clone 1 and three with BP1-KO clone 2, corresponding to approximately 195 cells for
each clone. C. Detection of blood stage parasitemia following injection of unruptured or mechanically
Rodent ortholog for falcipain-1 highlights differences between hepatic
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mice, parasitemia initially increased but then plateaued for a few days (Fig 5B), after which it
began to rise more rapidly. Mice inoculated with BP1-KO parasites died between days 14 and
19 post infection with high parasitemias. This is consistent with previous studies demonstrating
that attenuation of P. berghei ANKA parasites or manipulation of the host immune response,
prevents death from severe malaria [47–51]. Since the mice do not die an early death, the para-
sites continue to grow until high parasitemias ultimately kill the animal, likely from severe ane-
mia. These data suggest that in addition to the role in priming hepatic merozoites for invasion,
berghepain-1 has functions in the erythrocytic stage of the life cycle, consistent with a previous
ruptured merosomes. 5000 ruptured or unruptured merosomes of BP1-KO or BP1-CON parasites were injected
i.v. per Swiss Webster mouse. Average prepatent period of BP1-CON and BP1-KO clone 1 from two independent
experiments performed are shown.
https://doi.org/10.1371/journal.ppat.1006586.g004
Fig 5. Blood stage growth of berghepain-1 knockout parasites in mice. 104 or 105 red blood cells
infected with BP1-CON or BP1-KO parasites were injected i.v. into Swiss Webster mice. A. Parasitemia was
monitored daily and the average parasitemias of 5 mice per group is plotted. B. Data from days 1 through 10
shown in panel A, with an expanded Y-axis to highlight the differences in parasitemia in the early stage of
infection. Results of a representative experiment, from a total of 2 experiments, using two different doses of
BP1-KO clone 1, with a total of 5 mice per group, are shown.
https://doi.org/10.1371/journal.ppat.1006586.g005
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study which found a reduced blood stage growth rate for P. berghei berghepain-1 knockout par-
asites [13].
Blood stage phenotype of berghepain-1 knockout parasites can be
restored by pretreating mice with phenylhydrazine
The observed lag in parasite growth of BP1-KO asexual stages was reminiscent of the growth
pattern observed in the non-lethal strains of P. berghei and P. yoelii, which have a marked pref-
erence for invading reticulocytes [52–54], young erythrocytes newly released from the bone
marrow, which account for 1–3% of circulating erythrocytes in a non-anemic animal. For par-
asites with a reticulocyte preference, the plateau in parasitemia during the acute phase of infec-
tion reflects the depletion of available reticulocytes. This is followed by a rise in parasitemia as
a consequence of the ensuing anemia, which induces a reticulocytemia [52–54]. We hypothe-
sized that BP1-KO parasites are restricted to reticulocytes in manner similar to the non-lethal
rodent malaria parasites. To test this experimentally, we induced a transient reticulocytemia in
mice by pretreatment with the hemolytic agent phenylhydrazine (PHZ) [54]. Treated mice had
more than 48% reticulocytes compared to 1% - 4% reticulocytes in PBS-treated control mice.
Infecting PHZ-treated mice with BP1-KO parasites resulted in a rapid increase in parasitemia
comparable to BP1-CON during the early stages of infection, achieving high parasite burdens
and eliminating the plateau phase observed in PBS-treated mice infected with BP1-KO para-
sites (Fig 6A and 6B). Nonetheless, the effect of PHZ is temporary and by day 9 post-treatment
(day 6 of infection), reticuolocyte counts return to baseline [54,55] and parasitemia once again
plateaus. Of note, the parasitemia of PHZ-treated mice infected with BP1-CON parasites also
rose more rapidly than in PBS-treated mice, likely due to a reticulocyte preference of wild-type
P. berghei ANKA parasites. Furthermore, lethality, which is reduced in the BP1-KO parasite, is
enhanced by PHZ-treatment: while only 15% of PBS-treated mice infected with BP1-KO had
died by day 14, upon PHZ-treatment, 70% mice infected with BP1-KO parasites had died by
day 14 (Fig 6C). These data demonstrate that the growth delay and lethality of BP1-KO para-
sites can be restored by increasing the reticulocytes available for invasion, suggesting that ber-
ghepain-1 is involved in erythrocyte tropism, specifically in mediating infection of mature
erythrocytes.
Berghepain-1 is critical for normocyte invasion
To further characterize the reticulocyte preference of berghepain-1 knockout parasites, we
inoculated 10,000 synchronized BP1-CON and BP1-KO blood stage schizont parasites and
counted the number of parasites developing in reticulocytes versus normocytes from days 4 to
7 post infection. Infected reticulocytes were identified by simultaneous staining of blood
smears with Giemsa-stain and a stain for reticulin, which is specific for reticulocytes [56]. Par-
asite infectivity for each of the two erythrocyte populations was determined by expressing the
number of infected reticulocytes as a percentage of total infected red cells over days 4 to 7 post
infection (Fig 7A). While BP1-CON parasites had a preference for reticulocytes at days 4 and
5, with over 60% of parasites invading reticulocytes, this percentage dropped to below 20% as
the total parasitemia increased (Fig 7A). During early stages of infection, BP1-KO parasites
behaved similarly, with 75% of BP1-KO parasites developing in reticulocytes at day 4, however
in contrast to the BP1-CON parasite, this preference only marginally dropped over the follow-
ing days. These data suggest that reticulocytes are the preferred target cells for both control
and BP1-KO P. berghei parasites. However, as reticulocytes are consumed by the infection,
only control parasites are readily able to invade normocytes, supporting a role for berghepain-
1 in infection of mature erythrocytes.
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Fig 6. Blood stage growth of berghepain-1 knockout parasites in phenylhydrazine (PHZ)-treated
mice. Swiss Webster mice were pre-treated with PHZ (squares) or PBS (circles) with the last dose
administered 3 days prior to i.v. injection of 2x106 erythrocytes infected with BP1-CON or BP1-KO parasites.
Pooled results from three biological replicates are shown, two using BP1-KO clone 1 and one using BP1-KO
clone 2. A. Parasitemia was monitored daily and the average parasitemia of all surviving mice is plotted. B.
The graph displays the data from days 1 through 8 (boxed region of panel A), to highlight differences in
parasitemia in the early stage of infection. C. Survival curves of PHZ- and PBS-treated mice after infection
with BP1-CON and BP1-KO parasites. Mice were monitored for 30 days and the average survival rate of
infected mice is plotted.
https://doi.org/10.1371/journal.ppat.1006586.g006
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Fig 7. Berghepain-1 is important for normocyte invasion by blood stage parasites. A. Reticulocyte preference of berghepain-1 knockout
parasites. Swiss Webster mice were infected with 104 purified BP1-CON and BP1-KO blood stage schizonts and infected normocytes and reticulocytes
were counted starting 4 days after infection. Shown is the percentage of parasites found in reticulocytes on days 4–7 post infection. Each bar shows the
mean plus standard deviation of 5 mice (BP1-CON) and 10 mice (BP1-KO), the latter being pooled data from BP1-KO clone 1 (5 mice) and BP1-KO clone
2 (5 mice). Mean total parasitemia values are displayed above the individual columns. B. Growth of BP1-KO but not BP1-CON blood stage parasites
follow the reticulocyte count. Swiss Webster mice were injected i.v. with 2x105 BP1-KO or BP1-CON infected erythrocytes. Parasitemia and
reticulocytemia were monitored daily by Giemsa-stained blood smears and the average parasitemia of all surviving mice is plotted. n = 4 mice per group.
C. Normal cell cycle length of berghepain-1 knockout parasites. Infections in Swiss Webster mice were started by i.v. injection of 108 BP1-KO or
BP1-CON synchronized blood stage schizonts. Parasitemia was monitored hourly, counting ring stages and early trophozoites, and mid to late
trophozoites. Percentage of each parasite life cycle stage is plotted as percent of total parasitemia and pooled results from two experiments using BP1-KO
clone 1 are shown.
https://doi.org/10.1371/journal.ppat.1006586.g007
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To further confirm that the growth pattern of BP1-KO parasites was due to their reticulo-
cyte restriction, we inoculated BP1-KO and BP1-CON infected red blood cells i.v. into Swiss
Webster mice and monitored both parasitemia and reticulocyte counts over time. As expected,
control parasites grew rapidly despite low reticulocyte numbers and quickly killed the mice
(Fig 7B). In contrast, BP1-KO parasite growth followed the expansion of the reticulocyte pool,
initially growing to parasitemias of ~ 2 to 3%, then plateauing and only increasing after the
induction of a reticulocytosis (Fig 7B).
Since an overall longer cell cycle can also produce a slow-growing phenotype, we set out
to investigate whether the slow growth of berghepain-1 knockout blood stage parasites
could be due to a change in length of cell cycle. Synchronized blood stage schizonts were
injected into a mouse and hourly Giemsa-stained blood smears were used to monitor the
transition from G1 to S-phase, which occurs between early and mid-trophozoite stage [57].
Using percent of total parasites that were rings/early trophozoites versus mid/late trophozo-
ites as a readout for cell cycle duration, we found that BP1-KO parasites cell cycle mirrored
that of BP1-CON parasites (Fig 7C). It should be noted that the schizont stage of P. berghei
parasites adhere to endothelium and are not circulating; thus, after 20 h, numbers of circu-
lating parasites decreased as mature trophozoites developed into schizonts. Our data suggest
that the slower growth in BP1-KO parasites is due to a deficiency in infecting erythrocytes
rather than slower development.
Key role of berghepain-1 for hepatic merozoite infectivity
Our data demonstrate that deletion of berghepain-1 gives rise to a phenotype in both blood
stage and hepatic stage merozoites. We hypothesized that the role of berghepain-1 in these two
distinct populations of merozoites is not equivalent since BP1-KO merosome inoculation
results in a prepatent period delay of 5 days compared to control parasites (Fig 4) whereas
BP1-KO blood stage parasites are less attenuated (Figs 5–7). To directly compare the infectivity
of BP1-KO hepatic and blood stage merozoites, we compared the onset of detectable parasite-
mia in Swiss Webster mice inoculated with synchronized schizonts and merosomes. Mice
were injected i.v. with 1,000 or 10,000 purified blood stage schizonts derived from in vitro
overnight culture of blood stage BP1-CON and BP1-KO parasites or with 1,000 BP1-CON and
BP1-KO hepatic merosomes isolated from in vitro liver stage cultures. While schizonts contain
between 10 to 14 individual merozoites [58], merosomes are more variable, harboring between
100 and 1000 hepatic merozoites [3]. Mice injected with 1,000 or 10,000 BP1-CON blood stage
schizonts developed detectable parasitemia by day 4 and 3, respectively. After injection of the
same number of BP1-KO blood stage schizonts, a delay of 0.6 days and 1 day, respectively, was
seen compared to BP1-CON (Table 2). This was in stark contrast to mice injected with mero-
somes: while injection of BP1-CON merosomes led to detectable blood stage parasitemia
within one day, we did not detect parasites until 5.6 days after BP1-KO merosome inoculation.
Thus, the delay to patency of BP1-KO merosomes was greater by ~ 4 days compared to the
delay observed with BP1-KO blood stage schizonts.
Since the delay in prepatent period after inoculation of BP1-KO hepatic merozoites may in
part result from reduced invasion capacity of the erythrocytic merozoites in the ensuing blood
stage infection, we attempted to restore growth by inoculating merosomes into mice pretreated
with phenylhydrazine. This improved the infectivity of BP1-KO merosomes by ~ 1.5 days, sug-
gesting that the patency delay of BP1-KO merosomes reflects the combined delay in both pop-
ulations of merozoites. However, in contrast to blood stage merozoites, reticulocytosis does
not fully restore BPI-KO merozoite infectivity. Overall, these experiments demonstrate that
hepatic merozoites of the berghepain knockout parasite are significantly more impaired than
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erythrocytic merozoites and highlight that while both hepatic and erythrocytic merozoites
invade red blood cells, clear differences exist between the merozoites released from the liver
and those released from infected red blood cells.
Berghepain-1 is expressed in both blood and liver stage parasites
To investigate the timing and localization of berghepain-1 expression, we generated a parasite
line in which the endogenous berghepain-1 gene was fused to a triple myc tag, a short sequence
derived from the c-myc gene (S5 Fig). Using this line, we investigated whether berghepain-1 is
expressed at the protein level in blood stage parasites, performing immunofluorescence
microscopy of early and late blood stage schizonts. As shown in Fig 8, berghepain-1-myc is
expressed in early schizonts and the staining localizes to the individual merozoites in seg-
mented mature schizonts. We then investigated berghepain-1 expression during liver stage
development. Immunofluorescence microscopy of HepG2 cells infected with myc-tagged ber-
ghepain-1 parasites showed low levels of berghepain-1-myc expression at 24 h post infection,
which increased at 36 h in late hepatic trophozoite stages (Fig 9A). At 48 h post infection, ber-
ghepain-1-myc surrounded the individual nuclei and this perinuclear pattern was still present
at 56 h (Fig 9A). At 33 h post infection, berghepain-1-myc was also found in larger sub-com-
partments of the parasites, which co-localized with the staining of the ER marker BiP [59,60]
(Fig 9B). Berghepain-1-myc did not co-localize with cytosolic marker HSP70 [61], or the
membrane marker MSP1 (Fig 9A and 9C) or with CSP (S6 Fig). The specificity of the anti-c-
myc staining is demonstrated by the lack of staining of liver stages of the parental control line
(S7 Fig). Though these data demonstrate that berghepain-1 is expressed during liver stage
development, we did not, however, detect expression of berghepain-1-myc in merosomes, the
stage that is attenuated in berghepain-1 deletion mutants (Fig 9C). Thus, it is possible that ber-
ghepain-1 functions prior to the formation of merosomes, priming merozoites that will then
be packaged into merosomes for exit from the liver. We cannot, however, eliminate a role for
berghepain-1 in hepatic merozoites as it’s possible that expression levels in hepatic merozoites
Table 2. Liver and blood stage merozoite infectivity of berghepain-1 knockout parasites. Swiss Webster mice were injected i.v. with purified blood
stage schizonts or merosomes of BP1-CON and BP1-KO clone 1 parasites and parasitemia was monitored daily. In the last set of experiments, mice were


























10/10 PHZ-treated mice 1.00
BP1-KO 1,000
merosomes
10/10 PHZ-treated mice 4
https://doi.org/10.1371/journal.ppat.1006586.t002
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are too low to be detected by our methodology. The latter possibility is consistent with expres-
sion data of other proteases whose low abundance makes it difficult to detect [62,63].
Discussion
The function of falcipain-1, the most highly conserved member of the falcipain family of prote-
ases, has been the subject of some controversy. While an inhibitor of falcipain-1 blocked erythro-
cyte invasion by merozoites [23], two independent studies showed that falcipain-1 disruption did
not affect growth of blood stage parasites [29,30]. Since the rodent model affords a more in-depth
analysis of protein function across all life cycle stages of Plasmodium, we disrupted berghepain-1,
the falcipain-1 ortholog of the rodent parasite P. berghei, in an attempt to better understand the
role of this protease. Our study revealed that berghepain-1 has a role in erythrocyte infection by
Fig 8. Expression of berghepain-1 in blood stage parasites. Early (panel A) and late (panel B) blood stage
schizonts of transgenic berghepain-1-myc parasites and WT parasites stained with anti-c-Myc (magenta) to visualize
berghepain-1-myc, and anti-MSP1 (green) to visualize the merozoite membrane. Parasite DNA was stained with DAPI
(blue). Scale bars: 5 μm.
https://doi.org/10.1371/journal.ppat.1006586.g008
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Fig 9. Expression of berghepain-1 in liver stage parasites. HepG2 cells infected with BP1-myc parasites, and
merosomes collected from these cultures, were fixed at the indicated timepoints and probed with anti-c-myc antibodies
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both hepatic and erythrocytic merozoites. Furthermore, the impact of berghepain-1 deletion is
significantly more pronounced in hepatic merozoites, indicating that hepatic merozoites are not
identical to their blood stage counterparts.
An important role for berghepain-1 in erythrocyte infectivity by blood stage rodent malaria
parasites is supported by several lines of evidence: Berghepain-1 knockouts have a growth
delay, consistent with previous work [13], and reduced lethality, which can be restored, at least
temporarily, by increasing the pool of young erythrocytes. The reticulocyte tropism of berghe-
pain-1 knockout parasites was further confirmed by reticulin staining of infected cells, and
analysis of cell cycle duration showed normal development of the mutant parasite following
invasion, indicating that the defect in berghepain-1 knockout merozoites is specific to one or
more steps in the entry process rather than growth. Indeed, previous work showed that asexual
blood stages of berghepain-1 deletion mutants produce wild-type levels of hemozoin, suggest-
ing that unlike berghepain-2, the function of berghepain-1 is not associated with hemoglobin
digestion [13]. Our findings are supported by a previous study demonstrating that an inhibitor
of falcipain-1 impacts erythrocyte invasion by P. falciparum and the localization of falcipain-1
to the apical end of merozoites [23]. However, two subsequent studies showed that deletion of
falcipain-1 did not result in a blood stage growth phenotype [29,30], raising the possibility that
there are essential differences between the host cell invasion pathways used by rodent and
human parasites. Another possibility is that the selective pressure generated by many rounds
of replication during in vitro culture of P. falciparum could select for parasites that are able to
compensate invasion defects. Indeed, P. falciparum merozoites can invade erythrocytes using
multiple pathways and some of these may not rely on the activity of falcipain-1. This is sup-
ported by our observation that berghepain-1 knockout parasites are not dramatically inhibited
in erythrocytic stage growth, indicating that in the rodent parasites as well, alternate invasion
pathways are utilized by the BP1-KO parasites. Thus, taken together these data raise the possi-
bility that falcipain-1 and its orthologs have a conserved role across species.
Given the reticulocyte tropism of the BP1-KO parasite, we hypothesize that berghepain-1 is
involved in infection of mature erythrocytes, possibly by cleaving a parasite ligand required for
this process. This could function in initial adhesion to the host cell or in the invasion process,
either of which would be consistent with our data. Supporting this hypothesis is evidence that
cathepsin L, a falcipain-like protease in the related apicomplexan parasite Toxoplasma gondii,
was found to proteolytically mature adhesins as they traffic to micronemes, the specialized
secretory organelles whose regulated secretion is essential for invasion [64]. Though the sub-
strate(s) for berghepain-1 remain unknown, possible candidates include the rodent malaria
235 kDa rhoptry proteins [65,66], members of the reticulocyte-binding-like (RBL) protein
family found in all Plasmodium species and known to be involved in erythrocyte invasion. In
P. yoelii, Py235 proteins influence host erythrocyte preference and are associated with viru-
lence, with more virulent parasites invading a wider range of erythrocytes [37,67,68]. Interest-
ingly, distinct subsets of Py235 proteins are expressed in liver and blood stage parasites [69].
Future work involving mass spectrometric approaches that probe for potential cognate sub-
strates of berghepain-1 will shed additional light on the function of this protease.
We also found a critical role for berghepain-1 in the pre-erythrocytic stage of infection. The
pronounced delay in blood stage infection after sporozoite inoculation suggested that
(magenta) to localize berghepain-1, and co-localized with antibodies against A. the cytosolic marker heat-shock protein 70
(HSP70), B. the ER chaperone BIP (green) and C. the membrane maker merozoite surface protein 1 (MSP-1). BP1-myc
expression was low 24 h after invasion, but seen in early schizonts after 36 h of development. Host and parasite DNA were
stained with DAPI (blue). Scale bars: 10 μm.
https://doi.org/10.1371/journal.ppat.1006586.g009
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berghepain-1 functions at one or more steps between sporozoite localization to the liver and
initiation of blood stage infection. Experiments designed to test each stage of this process
revealed that injection of berghepain-1 knockout merosomes could replicate the pronounced
delay in blood stage infection after berghepain-1 knockout sporozoite inoculation. Additional
experiments with mechanically ruptured merosomes pinpointed the defect to a decreased
infectivity of merozoites arising from mature liver stage parasites. Given the expression of
BP1-myc during EEF development, this suggests a role for berghepain-1 in preparing hepatic
merozoites for infection of red blood cells.
Intriguingly, while these two distinct merozoite populations appear morphologically identi-
cal and are functionally similar in that both must invade red blood cells, we observed a more
significant attenuation of BKO-1 hepatic merozoites compared to their blood stage counter-
parts. Though we do not yet understand how the same protease differentially impacts these
distinct merozoite populations, there are two possible scenarios. One possibility is that the
same ligand is processed in blood stage and hepatic merozoites, with this event having a more
critical role in hepatic merozoite infectivity. Alternatively, berghepain-1 could have a different
role, possibly processing a different substrate, in each of these merozoite populations. Studies
with endogenously-tagged berghepain-1 showed that it localizes to merozoites of blood and
liver stage schizonts, but is not found in merosomes. These localization data are consistent
with either possibility since parasite egress from the mother cell differs in these two merozoite
populations. In the blood stage, PV rupture and erythrocyte membrane rupture occur in rapid
succession whereas in the liver, the formation of merosomes is an additional step, occurring
after PV rupture, and enabling hepatic merozoites to exit the liver sinusoid. Thus, if berghe-
pain-1 acts at some point prior to PV rupture in both merozoite populations, it is not surpris-
ing that the merosomes, with already primed merozoites, contain little berghepain-1.
Unfortunately, the small amount of hepatic merozoite material that can be collected combined
with the lack of an in vitro infectivity assay for hepatic merozoites, have made it difficult to
more precisely determine the hepatic merozoite defect. Future work focusing on identification
of the berghepain-1 substrate(s) will be critical to elucidating its role in hepatic and blood stage
merozoite infectivity.
Little is known about whether there are finer-scale differences between blood stage and
hepatic merozoites, with only one previous study addressing this topic. This elegant work
demonstrated that different Py235 family members are expressed in hepatic versus erythro-
cytic merozoites [69]. Based on their data, these authors suggested that hepatic and blood
stage merozoites differentially rely on distinct invasion pathways, a hypothesis that is sup-
ported by our data. This makes sense in light of the different biological niches of each mero-
zoite population. Given the bottleneck of sporozoite transmission, hepatic merozoites likely
originate from 1 to 5 infected hepatocytes and as a result, their numbers are 3 to 5 logs
lower than their blood stage counterparts [70]. Despite their low numbers, it is essential that
hepatic merozoites succeed in invading erythrocytes for if they fail, gametocytes will not be
produced for transmission to the mosquito. This is in contrast to blood stage merozoites
which are present in large numbers and thus risk killing the host, a scenario which would
also jeopardize transmission to the mosquito. Thus, while it is imperative for hepatic mero-
zoites to maximize their infectivity for erythrocytes, blood stage merozoites must walk a
line between maintaining infection and not killing the host. Therefore it is plausible that
these two populations of merozoites differ in their invasion pathways in ways that are more
complex than we can currently appreciate. Future work comparing liver and blood stage
merozoites to better understand their differences will help inform the search for suitable
drug targets for prophylactic or dual stage drug interventions.
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Materials and methods
Ethics statement
All animal work was conducted in accordance with the recommendations by New York Uni-
versity and Johns Hopkins University Animal Care and Use Committees (ACUC), under the
ACUC-approved protocols 110608, M011H467 and M014H363. All animal experiments per-
formed at the LUMC were approved by the Animal Experiments Committee of the Leiden
University Medical Center (12042). The Dutch Experiments on Animal Act were established
under European guidelines (EU directive no. 86/609/EEC regarding the Protection of Animals
used for Experimental and Other Scientific Purposes). All efforts were made to minimize suf-
fering. Experiments were performed in male and/or female 4- to 6-week-old Swiss Webster or
NMRI mice and C57BL/6 mice, purchased from Taconic and Charles River. Male Wistar-
Kyoto rats were also used for transfection experiments.
Generation of BP1-CON and BP1-KO parasite lines
Recombinant P. berghei BP1-CON and BP1-KO parasites were generated by double homol-
ogous recombination in which the native berghepain-1 locus was replaced with a selection
cassette (BP1-KO) or a wildtype copy of the berghepain-1 with the selection cassette
(BP1-CON). Targeting plasmid pBP1-KO was generated by flanking the human dihydrofo-
late reductase (hDHFR) cassette in plasmid pDEF-hDHFR-flirte [71] with 1.6 kb of the ber-
ghepain-1 5’ UTR and 1.3 kb of berghepain-1 3’ UTR, both cloned from gDNA (S1 Fig). For
the control construct pBP1-CON, 1.84 kb of the berghepain-1 5’ UTR, 1.56 kb of the berghe-
pain-1 ORF and 1.33 kb of the berghepain-1 3’ UTR were cloned from gDNA and inserted
into pDEF-hDHFR-flirte as outlined in S1 Fig. Transfection was performed using plasmid
digested with EcoR1 to liberate the DNA fragment, containing sequence from the 5’ and 3’
UTRs of berghepain-1, to drive double homologous recombination. P. berghei ANKA para-
sites clone 507cl1 [31], were electroporated with 5 μg of digested plasmid DNA, injected
into mice, selected with pyrimethamine and cloned by limiting dilution in mice, following
standard procedures [72].
Generation of berghepain-1-myc expressing parasites
The reporter line, PbGFP-Lucschz (line 1037cl1; www.pberghei.eu mutant RMgm-32;) was
used to generate the transgenic berghepain-1-myc line. In this line, the gfp-luc expression
cassette is stably integrated into the 230p locus without introduction of a drug-selectable
marker and is under the control of the blood stage schizont-specific ama1 promoter [50].
The berghepain-1 ORF (without its stop codon) was PCR-amplified from wild type P. ber-
ghei ANKA genomic DNA with primer sets L7424/L7425 (see S1 Table). This PCR product
was digested with SpeI and BamHI, and C-terminally fused to a triple c-myc tag by ligation
into the SpeI/BamHI digested vector pL1612, resulting in construct pL2018 (S5 Fig). Prior
to transfection, pL2018 was linearized with AflII. Transfection, selection and cloning of
transgenic parasites with pyrimethamine were carried out as described previously [72], gen-
erating the transgenic line berghepain-1-myc (line 2338), expressing endogenously C-ter-
minally tagged berghepain-1.
Mosquito infection
Anopheles stephensi mosquitoes were reared using standard procedures and fed on Swiss-Web-
ster mice infected with the indicated parasite line. On day 13 after infective blood meal, mos-
quitoes were dissected and the midguts were observed for oocyst counts using an upright
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Nikon E600 microscope with a phase contrast PlanApo 10x objective. For salivary gland sporo-
zoite numbers, salivary glands were harvested on day 19 after infective blood meal from 20
mosquitoes and counted on a hemocytometer.
Sporozoite gliding motility assay
Sporozoite gliding motility was assayed as previously described [25]. Glass 8-chambered Lab-
tek wells (ThermoScientific) were coated with 10 μg/μl mAb 3D11, specific for the repeat
region of the P. berghei circumsporozoite protein [73], in PBS overnight at 25˚C. Salivary
gland sporozoites in 3% BSA in Dulbecco’s Modified Eagle Medium (DMEM) were added to
each well and incubated for 1 h at 37˚C. Wells were fixed in 4% paraformaldehyde and trails
were visualized by staining with biotinylated mAb 3D11, followed by detection with strepativin
conjugated to FITC (Amersham). Trails associated with sporozoites and the number of circles
per trail were counted using fluorescence microscopy on an upright Nikon E600 and 40x
objective.
Sporozoite infectivity as determined by prepatent period
To examine sporozoite infectivity in vivo, 4- to 6-week-old Swiss Webster or C57BL/6 mice
were inoculated i.v. with the indicated number of sporozoites in DMEM. The onset of blood
stage infection was determined by daily observation of Giemsa-stained blood smears, begin-
ning on day 3 after inoculation. For intradermal inoculation, mice were lightly anesthetized by
intraperitoneal injection of ketamine/xylazine (35–100 μg ketamine/g body weight) and main-
tained at 37˚C on a slide warmer. Sporozoites were injected into the ear pinna, in a total vol-
ume of 0.2 μl DMEM, with a Flexifill microsyringe (World Precision Instruments).
Sporozoite infectivity as determined by quantification of liver stage
parasite burden
To examine in vivo sporozoite development in the liver, 4- to 6-week-old Swiss Webster or
C57BL/6 mice were inoculated i.v. with 10,000 sporozoites in 200 μl of DMEM. 40 h later,
livers were harvested for total RNA isolation and infection was quantified using reverse
transcription followed by real-time PCR, using primers that recognize P. berghei–specific
sequences within the 18S rRNA, as outlined previously [74]. Copy number was ascertained
by comparison with a plasmid standard curve.
Parasite development in hepatocyte cultures
Cells of the human hepatoma cell line HepG2 (ATCC, HB-8065) were maintained in DMEM
supplemented with 1 mM L-glutamine, 10% Fetal Calf Serum and 5 mg⁄mL penicillin/strepto-
mycin (complete medium) at 37˚C and 5% CO2, as previously described [75]. 2.5 x 10
5 HepG2
cells per well were plated onto coverslips coated with collagen I (BD Biosciences #354236) and
grown for 8–12 h in 24-well plates. Sporozoites were dissected in DMEM and 4–6 x 104 sporo-
zoites were added per well. After sporozoites were allowed to invade for 2 h at 37˚C, free spo-
rozoites were removed by washing with complete medium containing 5μg/mL Fungizone
(Cellgro 30-003-CF) and 10X penicillin/streptomycin (wash medium), and then maintained in
complete medium. Cells were washed twice per day with wash medium until the indicated
timepoint, when they were fixed with 4% paraformaldehyde (PFA) and mounted. EEFs were
observable due to their GFP-expression, and total EEFs per coverslip were manually counted.
For immunofluorescence assays, EEFs were stained as outlined below.
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Merosome production and harvest
To quantify the formation of merosomes, HepG2 cells were grown at a density of 50,000 cells
per well of a 24-well plate and infected as described above. At 50 h post infection, culture
supernatant volume was reduced to 0.5 ml medium/well. Culture supernatant containing
merosomes was collected between 60 and 65 h post infection using a pasteur pipette and
counted using a hemocytometer. Merosomes (numbers depending on the experiment) were
injected i.v. into Swiss Webster mice for prepatent period experiments. For mechanical rup-
ture assays, 25 merosomes per μl in a total volume of 1 ml were sheared by 10 strokes through
a 30 gauge needle using a 1 ml syringe and within 5 min were injected i.v. into mice. Samples
from ruptured and control merosomes were fixed in 0.4% PFA and nuclei were stained with
DAPI to allow microscopic analysis of rupture, which revealed that 98% of merosomes were
ruptured by the procedure.
Cell elasticity measurement on merosomes cells
For atomic force microscopy experiments, infection with BP1-CON and BP1-KO clones 1 and
2 was allowed to proceed in HepG2 cells until 65 h post infection, when merosomes were col-
lected from the culture supernatant. Total medium from two infected wells of a 24-well plate
was collected in a 1.5 ml tube and merosomes were allowed to settle for 15 min at room tem-
perature. Medium was then carefully removed to leave ~30–50 μl containing the merosomes
and 500 μl of 1% PFA was added to fix the merosomes, in order to stop their movement. After
3 min, 1 ml of PBS was added and merosomes were again allowed to settle for 15 min at room
temperature. The paraformaldehyde solution was removed, leaving 30–50 μl and 150 μl
DMEM was added to the merosomes. Nanoindentation experiments were carried out at 25˚C
using an atomic force microscope NanoWizard II (JPK Instruments, Berlin, Germany)
mounted on the top of an Axiovert 200 inverted microscope (Carl Zeiss, Jena, Germany). Mea-
surements were made using non-functionalized OMCL TR-400-type silicon nitride tips
(Olympus, Japan). Tip spring constants were calibrated by the thermal fluctuation method,
having a nominal value of 0.02 N/m. For cell contact, the distance between the cantilever and
the cell was adjusted to maintain a maximum applied force of 800 pN before retraction. Data
collection for each AFM force-distance cycle was performed at 1.5 Hz and with a z-displace-
ment range of 8 μm. The acquired force curves were analyzed using JPK Image Processing v.
4.2.53, by the application of the Hertzian model, to obtain the cells Young’s modulus (E). The
AFM probe was modeled as a quadratic pyramid, with a tip angle of 35˚ (half-angle to face)
and a Poisson ratio of 0.50. For data analysis, multiple readouts of Young’s modulus from a
single cell were averaged and the mean used to represent the value for that cell. Rare outlier
values above 300 Pa were discarded, though statistical significance of variance between
BP1-CON and BP1-KO populations did not change if they were included.
Immunofluorescence assays of EEFs and merosomes
For IFAs of EEFs, wells with infected HepG2 were washed and fixed in 4% paraformaldehyde/
PBS for 1 h at room temperature. For IFAs of merosomes, supernatants were collected and
spun at 50xg onto poly-L-lysine-coated coverslips and fixed for 20 min with 4% PFA at room
temperature. Both EEF and merosomes were permeabilized in methanol overnight at -20˚C
and blocked with 1% BSA/PBS for 1 h at room temperature before incubation with primary
and secondary antibodies for 1 h each at room temperature. The following antibodies were
used, diluted in 1% BSA/PBS: mouse anti-MSP 25.1 diluted 1:500 [37], polyclonal rabbit anti-
UIS4 diluted 1:5000 [41], mouse anti-CSP at 1 μg/ml [clone 3D11; [73]], mouse anti-Plasmo-
dium HSP-70 diluted 1:500 [clone 2E6; [61]], mouse anti-BiP diluted 1:200 [60], and rabbit
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anti-c-myc diluted 1:400 (C3956, Sigma). Secondary antibodies used were anti-mouse Alexa
Fluor 488 conjugate (A11029, ThermoFisher) and anti-rabbit Alexa Fluor 594 conjugate
(A11012, ThermoFisher), each diluted 1:500. Samples were preserved in Prolong Gold mount-
ing medium containing DAPI (Life Technologies). Images for Figs 2 and 3 were acquired
using an upright Nikon 90i fluorescence microscope and a 40x objective. Images for Fig 5, S5
and S6 Figs were acquired using a LSM700 laser scanning confocal microscope (Zeiss AxioOb-
server) with a 63x/1.4 PlanApo oil objective using Zen software.
Immunofluorescene assays of blood stages
Thin blood smears were air-dried, fixed with 4% paraformaldehyde/PBS, permeabilized with
0.1% Triton X-100/PBS and blocked with 3% BSA/PBS before incubation with primary and
secondary antibodies. Rabbit anti-c-myc antibody (C3956, Sigma) was diluted 1:400 and
mouse anti-MSP 25.1 [37] was diluted 1:2000 in 1% BSA/PBS. Secondary detection was with
anti-mouse Alexa Fluor 488 conjugate (A11029, ThermoFisher) and anti-rabbit Alexa Fluor
594 conjugate (A11012, ThermoFisher), each diluted 1:500. Samples were preserved in Pro-
long Gold mounting medium containing DAPI (Life Technologies) and imaged using a
LSM700 laser scanning confocal microscope (Zeiss AxioObserver) with a 63x/1.4 PlanApo oil
objective and images were acquired using Zen software.
Phenylhydrazine treatment
Mice were treated with phenylhydrazine (PHZ; Sigma-Aldrich, P26252) dissolved in PBS pH
7.4, delivered intraperitoneally at 100 μg/g of body weight. Three total doses were given,
administered every other day, and mice were injected with infected red blood cells three days
after the final dose. To monitor reticulocyte numbers, blood smears were Giemsa-stained and
reticulocytes, which stain blue due to residual RNA, were counted as a percentage of total
erythrocytes.
Schizont culture
For culture of P. berghei schizonts, cardiac blood at 2–3% blood stage parasitemia was collected
from 2 to 4 Swiss Webster mice and was incubated in RPMI-1640 (Invitrogen) supplemented
with 10% FCS and gentamycin for 16–23 h, gently shaking at 80 rpm in culture flasks that
were flushed with 5% CO2, 5% O2, 90% N2 as described previously [72].
Staining of parasitized reticulocytes
To quantify the number of parasites developing in reticulocytes versus normocytes, mice were
inoculated i.v. with 10,000 BP1-CON and BP1-KO schizont stage parasites, obtained from in
vitro culture as described above. Blood smears of infected mice were stained using a Brilliant
cresyl blue and Giemsa double staining technique described previously [56]. Briefly, micro-
scope slides were coated with 0.3% Brilliant Cresyl Blue (BCB) in 95% ethanol and dried over-
night. These slides were incubated for 15 min at room temperature to allow absorbance of
BCB, followed by methanol fixation and standard Giemsa staining [56]. Parasites in BCB-
staining cells and cells not stained with BCB were counted.
Cell cycle length determination
Growth assays for cell cycle determination were started with i.v. injection of 108 synchronized
schizonts, obtained from overnight culture of BP1-CON and BP1-KO blood stage parasites as
above. Giemsa-stained blood smears were performed hourly for the next 30 h and scored as to
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the percent of total infected cells that were rings/early trophozoites versus mid/late trophozo-
ites. Since the G1-S transition in blood stage Plasmodium parasites occurs as the parasite tran-
sitions from early and mid-stage trophozoite [57], these counts are indicative of the time it
takes for the parasite to go through its cell cycle. At ~ 21 hours, schizonts begin to develop and
their sequestration meant we could only follow parasite growth up to this time [76]. Though P.
berghei is synchronous for up to 2 cycles [77], we found that the synchronicity of the second
cycle was not as tight, making it difficult to obtain accurate cell cycle data after the first cycle.
Supporting information
S1 Fig. Targeting strategy to generate berghepain-1 knockout parasites. A. To generate the
targeting plasmid pBP1-KO, 1.6 kb of berghepain-1 5’ UTR and 1.3 kb of berghepain-1 3’ UTR
were cloned from gDNA and inserted into pDEF-hDHFR-flirte plasmid [71], upstream and
downstream of the human dihydrofolate reductase (hDHFR) cassette. For transfection, the
plasmid was digested with EcoR1 to allow for double homologous recombination. B. To gener-
ate the targeting plasmid pBP1-CON, 1.84 kb of the berghepain-1 5’ UTR, 1.56 kb of the ber-
ghepain-1 ORF and 1.33 kb of the berghepain-1 3’ UTR were cloned from gDNA and inserted
into pDEF-hDHFR-flirte upstream and downstream of the human dihydrofolate reductase
(hDHFR) cassette. For transfection, the plasmid was digested with EcoR1 to allow for double
homologous recombination. C. Following transfection, diagnostic PCRs were performed on
clonal BP1-CON (BCON) and BP1-KO (BKO) lines, confirming correct 5’- and 3’-integration
of the construct, and absence of berghepain-1 ORF in the BP1-KO clones and presence of the
hDHFR selection marker cassette. Two BP1-KO clones (clones 1 and 2) were characterized
and used for experiments. Location of primers used for PCR analysis and sizes of PCR prod-
ucts are shown. See S1 Table for all primer sequences.
(TIF)
S2 Fig. The falcipain-1 inhibitor YA29 verifies berghepain-1 deletion. A. Structure of
BMV109, a broad-spectrum cathepsin probe, which labels most cysteine proteases [78] B.
BP1-CON and BP1-KO mixed blood stage parasite pellets were lysed and incubated in pres-
ence of the falcipain 1 inhibitor YA29 [23] prior to labelling with Cy5-BMV109. The berghe-
pain-1 band between 17 and 24 kDa decreases in intensity in presence of YA29 in the
BP1-CON lysate, but is not present in the BP1-KO lysate.
(TIF)
S3 Fig. Normal growth of berghepain-1 knockout liver stage parasites after intradermal
inoculation of sporozoites. Infections were performed by intradermal injection of 10,000
BP1-CON or BP1-KO clone 2 sporozoites into Swiss Webster mice. RT-qPCR analysis of liver
RNA 40 h post infection found no significant reduction of BP1-KO growth in the liver, as mea-
sured by parasite 18S rRNA copy number.
(TIF)
S4 Fig. Normal merosome formation in berghepain-1 knockout liver stage parasites
BP1-KO clone 1. HepG2 cell monolayers were infected with BP1-CON and BP1-KO parasites,
and after 48 h of in vitro culture, the number of EEFs per 50 fields of view, and after 65 h the
number of merosomes per 20 fields of view, were counted. Results of one representative exper-
iment, of a total of 2 experiments, performed using BP1-CON and BP1-KO clone 1 is shown.
(TIF)
S5 Fig. Generation of transgenic lines expressing C-terminally tagged berghepain-1. A.
Schematic representation of the tagging construct pL2018 targeting berghepain-1 by single
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cross-over homologous recombination, and the locus before and after tagging in reporter line
1037cl1, which contains ama1-gfp-luciferase expression cassette at the 230p locus. The tagging
construct contains C-terminal triple c-myc (orange box) and the tgdhfr/ts drug selectable
marker cassette (black box). Double lines indicate the enzyme site used for construct lineariza-
tion. B. Southern blotting analysis of pulsed field gel-separated chromosomes confirm correct
integration of the tagging construct. Chromosomes of the berghepain-1-myc parasite line 2338
were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into ber-
ghepain-1 locus on chromosome 13, the endogenous dhfr/ts gene on chromosome 7, and the
ama1-gfp-luciferase cassette at 230p on chromosome 3. C. Western blotting analysis of mixed
blood stages of the berghepain-1-myc line 2338 and the parental line 1037cl1 and probed with
anti-c-myc antiserum showing expression of berghepain-1-myc (60 kDa), and an unspecific
band at ~75 kDa, serving as a loading control for the parental line.
(TIF)
S6 Fig. Expression of berghepain-1 in liver stage parasites. HepG2 cells infected with ber-
ghepain-1-myc parasites were fixed at the indicated timepoints, probed with anti-CSP (green)
and anti-c-myc (magenta). Host and parasite DNA were stained with DAPI (blue). Scale bars:
10 μm.
(TIFF)
S7 Fig. Immunofluorescene assays of liver stage control parental parasites probed with
anti-c-myc. HepG2 cells infected with control parasites (1037cl1) were fixed at the indicated
timepoints, stained for CSP (green) and anti-c-myc (magenta), confirming specificity of the
anti-c-myc antiserum. Host and parasite DNA were stained with DAPI (blue). Scale bars:
10 μm.
(TIF)
S1 Table. Primers used for genotype analysis.
(TIF)
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